
Danielle M Enserro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8202087/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Missing repeated measures data in clinical trials. Neuro-Oncology Practice, 2022, 9, 35-42.	1.6	5
2	Lifetime Risk of HeartÂFailure Among Participants in the Framingham Study. Journal of the American College of Cardiology, 2022, 79, 250-263.	2.8	13
3	Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study. Circulation, 2022, 145, 1324-1338.	1.6	19
4	Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers. Gynecologic Oncology, 2021, 160, 625-632.	1.4	12
5	Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). Gynecologic Oncology, 2021, 161, 382-388.	1.4	7
6	Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology, 2021, , .	1.4	1
7	Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. JAMA Oncology, 2020, 6, 92.	7.1	69
8	Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). Clinical Cancer Research, 2020, 26, 5621-5630.	7.0	34
9	Clinical course after a first episode of heart failure: insights from the Framingham Heart Study. European Journal of Heart Failure, 2020, 22, 1768-1776.	7.1	8
10	Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. Obstetrical and Gynecological Survey, 2020, 75, 165-166.	0.4	2
11	Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. New England Journal of Medicine, 2019, 381, 1929-1939.	27.0	217
12	Measures for evaluation of prognostic improvement under multivariate normality for nested and nonnested models. Statistics in Medicine, 2019, 38, 3817-3831.	1.6	6
13	Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. Journal of Clinical Oncology, 2019, 37, 2317-2328.	1.6	289
14	Recontact practices of cancer genetic counselors and an exploration of professional, legal, and ethical duty. Journal of Genetic Counseling, 2019, 28, 836-846.	1.6	6
15	The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study. Gynecologic Oncology, 2019, 154, 13-21.	1.4	8
16	Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiology, 2018, 3, 215.	6.1	186
17	Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community. Open Heart, 2018, 5, e000722.	2.3	27
18	Comorbidities and CardiometabolicÂDisease. JACC: Heart Failure, 2018, 6, 317-325.	4.1	20

DANIELLE M ENSERRO

#	Article	IF	CITATIONS
19	Predictors and outcomes of heart failure with midâ€range ejection fraction. European Journal of Heart Failure, 2018, 20, 651-659.	7.1	91
20	Twenty‥ear Trends in the American Heart Association Cardiovascular Health Score and Impact on Subclinical and Clinical Cardiovascular Disease: The Framingham Offspring Study. Journal of the American Heart Association, 2018, 7, .	3.7	76
21	Temporal Trends in the Incidence ofÂandÂMortality Associated With HeartÂFailure With Preserved and Reduced Ejection Fraction. JACC: Heart Failure, 2018, 6, 678-685.	4.1	290
22	Left Ventricular Diastolic Dysfunction in the Community: Impact of Diagnostic Criteria on the Burden, Correlates, and Prognosis. Journal of the American Heart Association, 2018, 7, .	3.7	43
23	Racial Differences in Hospital Death for Atrial Fibrillation: The National Inpatient Sample 2001-2012. , 2018, 1, 1005.		1
24	Association of Parental Obesity and Diabetes Mellitus With Circulating Adipokines in Nonobese Nondiabetic Offspring. Journal of the American Heart Association, 2017, 6, .	3.7	10
25	Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study. Journal of the American Heart Association, 2016, 5, .	3.7	34
26	Cardiovascular Health Status and Incidence of Heart Failure in the Framingham Offspring Study. Circulation: Heart Failure, 2016, 9, e002416.	3.9	45
27	Association of Ideal Cardiovascular Health With Vascular Brain Injury and Incident Dementia. Stroke, 2016, 47, 1201-1206.	2.0	101
28	Association of Parental Hypertension With Arterial Stiffness in Nonhypertensive Offspring. Hypertension, 2016, 68, 584-589.	2.7	29
29	Biomarkers for the prediction of venous thromboembolism in the community. Thrombosis Research, 2016, 145, 34-39.	1.7	14
30	Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages inÂthe Community. JACC: Heart Failure, 2016, 4, 808-815.	4.1	72
31	Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study. Atherosclerosis, 2016, 248, 245-251.	0.8	53
32	Association of Exhaled Carbon Monoxide With Stroke Incidence and Subclinical Vascular Brain Injury. Stroke, 2016, 47, 383-389.	2.0	15
33	Association of exhaled carbon monoxide with subclinical cardiovascular disease and their conjoint impact on the incidence of cardiovascular outcomes. European Heart Journal, 2014, 35, 2980-2987.	2.2	19
34	Ideal Cardiovascular Health. Circulation, 2014, 130, 1676-1683.	1.6	179
35	Cardiometabolic Correlates and Heritability of Fetuin-A, Retinol-Binding Protein 4, and Fatty-Acid Binding Protein 4 in the Framingham Heart Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1943-E1947.	3.6	56